APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PALACE 4 PHASE 3, RANDOMIZED, CONTROLLED TRIAL

被引：2
|
作者：
Edwards, C. [1 ]
Wells, A. [2 ]
Adebajo, A. [3 ]
Kivitz, A. [4 ]
Bird, P. [5 ]
Shah, K. [6 ]
Hu, C. [6 ]
Stevens, R. M. [6 ]
Aelion, J. [7 ]
机构：
[1] Southampton Univ Hosp, Southampton, Hants, England
[2] Rheumatol & Immunotherapy Ctr, Franklin, TN USA
[3] Univ Sheffield, Sheffield, S Yorkshire, England
[4] Altoona Ctr Clin Res, Duncansville, PA USA
[5] Combined Rheumatol Practice, Kogarah, NSW, Australia
[6] Celgene Corp, Summit, NJ USA
[7] West Tennessee Res Inst, Jackson, MS USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.1574
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0389
引用
收藏
页码：735 / 735
页数：1
相关论文
共 50 条
  • [1] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
    Edwards, Christopher J.
    Aelion, Jacob A.
    Adebajo, Adewale O.
    Kivitz, Alan
    Bird, Paul
    Hu, ChiaChi
    Stevens, Randall M.
    Wells, Alvin
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S694 - S695
  • [2] Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials
    Gladman, Dafna D.
    Mease, Philip J.
    Kavanaugh, Arthur
    Adebajo, Adewale O.
    Gomez-Reino, Juan J.
    Wollenhaupt, Juergen
    Cutolo, Maurizio
    Schett, Georg
    Lespessailles, Eric
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher J.
    Birbara, Charles A.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S347 - S347
  • [3] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials
    Gladman, Dafna
    Mease, Phillip
    Kavanaugh, Arthur
    Adebajo, Adewale
    Gomez-Reino, Juan
    Wollenhaupt, Juergen
    Cutolo, Maurizio
    Schett, Georg
    Lespessailles, Eric
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall
    Edwards, Christopher
    Birbara, Charles
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1449 - 1449
  • [4] Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2)
    Cutolo, Maurizio
    Myerson, Gary E.
    Fleischmann, Roy M.
    Liote, Frederic
    Diaz-Gonzalez, Federico
    Van den Bosch, Filip
    Marzo-Ortega, Helena
    Feist, Eugen
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Poder, Airi
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S346 - S347
  • [5] Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)
    Kavanaugh, A.
    Mease, P.
    Adebajo, A.
    Wollenhaupt, J.
    Hu, A.
    Shah, K.
    Stevens, R.
    Gomez-Reino, J.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 131 - 131
  • [6] LONG-TERM (52-WEEK) RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS
    Kavanaugh, A.
    Mease, P. J.
    Adebajo, A. O.
    Wollenhaupt, J.
    Hu, C.
    Shah, K.
    Stevens, R. M.
    Gomez-Reino, J. J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 163 - 163
  • [7] PALACE 4, A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, FOR TREATMENT OF PSORIATIC ARTHRITIS: LONG-TERM (52-WEEK) IMPROVEMENTS IN PHYSICAL FUNCTION
    Wells, A.
    Edwards, C.
    Adebajo, A. O.
    Kivitz, A. J.
    Bird, P.
    Shah, K.
    Hu, C.
    Stevens, R. M.
    Aelion, J. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 732 - 732
  • [8] LONG-TERM 52-WEEK RESULTS OF PALACE 1, A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS
    Adebajo, Adewale O.
    Kavanaugh, Arthur
    Mease, Philip J.
    Wollenhaupt, Juergen
    Hu, ChiaChi
    Shah, Kamal
    Stevens, Randall M.
    Gomez-Reino, Juan J.
    [J]. RHEUMATOLOGY, 2014, 53 : 141 - 141
  • [9] Long-term 52-week results of PALACE 1, a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase inhibitor, in patients with psoriatic arthritis
    Adebajo, A.
    Gomez-Reino, J.
    Mease, P.
    Wollenhaupt, J.
    Hu, C. C.
    Shah, K.
    Stevens, R.
    Kavanaugh, A.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 12 - 12
  • [10] LONG-TERM 52-WEEK RESULTS OF PALACE 3, A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS AND CURRENT SKIN INVOLVEMENT
    Edwards, Christopher J.
    Blanco, Francisco J.
    Crowley, Jeffrey
    Hu, ChiaChi
    Stevens, Randall M.
    Birbara, Charles A.
    [J]. RHEUMATOLOGY, 2014, 53 : 138 - 139
12345